Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.

A composite implant for providing simultaneous magnetic resonance imaging (MRI) and computed tomographic (CT) imaging contrast is disclosed. The composite implant is formed of a calcium compound in the form of nano or microparticles doped with a first dopant configured to provide MRI contrast and a second dopant configured to provide CT contrast. The calcium compound is loaded onto a polymer gel matrix and lyophilized to form a mass with 3-dimensionally interconnected porosity, configured to provide tissue integration and proliferation sites. Methods of forming the composite implant are also disclosed. The implant could be a scaffold or bead structured to enable treatment of human or animal patient for bone/cartilage injury or defect by implantation, with MRI and CT monitoring.

A composite implant for providing simultaneous magnetic resonance imaging (MRI) and computed tomographic (CT) imaging contrast is disclosed. The composite implant is formed of a calcium compound in the form of nano or microparticles doped with a first dopant configured to provide MRI contrast and a second dopant configured to provide CT contrast. The calcium compound is loaded onto a polymer gel matrix and lyophilized to form a mass with 3-dimensionally interconnected porosity, configured to provide tissue integration and proliferation sites. Methods of forming the composite implant are also disclosed. The implant could be a scaffold or bead structured to enable treatment of human or animal patient for bone/cartilage injury or defect by implantation, with MRI and CT monitoring.

Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

The present invention provides a peptide comprising the amino acid sequence of any of the formulas (I)-(III) below:

(I) an amino acid sequence of (X1) [D] P [D] (X2) [D] wherein X1 is W or F, X2 is S or T, and each amino acid symbol immediately followed by symbol [D] is a D form of the amino acid,
(II) an amino acid sequence of P[D]T[D] (X).sub.n F[D] wherein (X).sub.n is any amino acid in the number of n selected independently of each other, n is an integer of 0-4, and the symbol [D] is as defined above,
(III) an amino acid sequence that is a Retro-inverso of the amino acid sequence of any of the aforementioned (I) and the aforementioned (II);
and a conjugate containing the peptide and a functional part.

The present invention provides a peptide comprising the amino acid sequence of any of the formulas (I)-(III) below:

(I) an amino acid sequence of (X1) [D] P [D] (X2) [D] wherein X1 is W or F, X2 is S or T, and each amino acid symbol immediately followed by symbol [D] is a D form of the amino acid,
(II) an amino acid sequence of P[D]T[D] (X).sub.n F[D] wherein (X).sub.n is any amino acid in the number of n selected independently of each other, n is an integer of 0-4, and the symbol [D] is as defined above,
(III) an amino acid sequence that is a Retro-inverso of the amino acid sequence of any of the aforementioned (I) and the aforementioned (II);
and a conjugate containing the peptide and a functional part.

The teachings generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an v3 antagonist with an 21 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

The invention involves assays, diagnostics, kits, and assay components for determining levels of glycated CD59 in the assessment of gestational diabetes mellitus and/or related disorders and/or conditions.

The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.

A bone biospecific agent comprises a contrast material core, which is visible using Magnetic Resonance Imaging (MRI) or Computed Tomography (CT). The contrast material core is surrounded by a polymeric shell, which is functionalised with a bone-targeting peptide. In use, the peptide targets the biospecific agent to bone. The bone biospecific agent can be used in diagnostic imaging techniques, such as MRI and CT, and in imaging bone remodelling activities, detecting and treating pathological bone conditions and/or bone repair processes. The invention extends to the diagnosis and/or treatment of bone disease and bone pathologies using the biospecific agents.